Shares of Endo International plc – Ordinary Shares (NASDAQ:ENDP) ended Monday session in red amid volatile trading. The shares closed down -1.40 points or -5.99% at $21.99 with 8.55 million shares getting traded. Post opening the session at $23.29, the shares hit an intraday low of $21.77 and an intraday high of $23.44 and the price vacillated in this range throughout the day. The company has a market cap of $5.21 billion and the numbers of outstanding shares have been calculated to be 222.77 million shares.
Endo International plc – Ordinary Shares (ENDP) on Sept. 23, 2016 announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately. Mr. Campanelli currently serves as President of Endo’s Generic and OTC drugs business, Par Pharmaceutical, which accounts for approximately 60 percent of Endo’s total revenues through the first half of 2016. Campanelli, who will also join Endo’s Board of Directors, succeeds Rajiv De Silva , who has stepped down as President, CEO and a member of the Board.
Campanelli, 54, joined Endo in 2015 following Endo’s acquisition of Par Pharmaceutical, where he had served as Chief Executive Officer since 2012. While CEO of Par, Campanelli built a strong leadership team and an industry-leading generics business. Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market. Since joining Endo, Campanelli has overseen the Company’s U.S. Generic Pharmaceuticals business.
“Given the continued evolution of Endo’s business and Paul’s impressive track record of delivering strong operating results, the Board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. Branded, U.S. Generic and International pharmaceutical assets,” stated Roger H. Kimmel , Chairman of the Board of Endo. “Paul has spent a significant portion of his career leading and operating complex generics businesses and overseeing Par’s branded business. The Board believes his experience positions him to drive a broad range of growth initiatives across Endo’s entire portfolio, generating better health outcomes for patients and creating value for Endo’s shareholders.”
Shares of Boston Scientific Corporation (NYSE:BSX) ended Monday session in green amid volatile trading. The shares closed up +0.02 points or 0.08% at $23.73 with 8.16 million shares getting traded. Post opening the session at $23.59, the shares hit an intraday low of $23.51 and an intraday high of $23.81 and the price vacillated in this range throughout the day. The company has a market cap of $32.26 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) on Sept. 19, 2016 received CE Mark for the LOTUS Edge™ Valve System, the company’s next generation transcatheter aortic valve implantation (TAVI) technology. The LOTUS Edge valve system is indicated for aortic valve replacement in patients with severe aortic stenosis who are considered at high risk for surgical valve replacement. Instead of open heart surgery, the replacement valve is delivered via transcatheter percutaneous delivery, a minimally invasive procedure involving a small incision to gain access to a blood vessel.
In comparison to the Lotus™ Valve System, this next iteration incorporates a more flexible, lower profile catheter designed to improve ease of use and accommodate tortuous anatomy. Another differentiating feature of the LOTUS Edge valve system is the inclusion of Depth Guard™, a design element intended to reduce the need for a permanent pacemaker (PPM).
“The LOTUS Edge device is a highly anticipated next generation of the Lotus Valve System,” said Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. “It retains many of its predecessor’s unique and valuable proprietary features, including the ability to reposition the device precisely and prevent paravalvular leak, while incorporating new design characteristics such as a more flexible catheter for easier delivery and Depth Guard™ technology designed to reduce valve interaction with the conduction system of the heart during valve deployment.”